Group 1 - Oscar Health (NYSE: OSCR) was initially rated as a "Buy" in March 2025, with the stock price falling to $12 before recovering to the $16 range [1] - MMMT Wealth, managed by Oliver, focuses on investment strategies and stock analysis, leveraging insights from investor calls, presentations, and financials [1] - Oliver has 5 years of investing experience and 4 years as a CPA, emphasizing the importance of thorough research in identifying high-potential businesses [1]

Your Medicare MatchmakerTM Investor Presentation August 2024 ©2024 eHealthInsurance Services, Inc. Safe Harbor Statement Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks include those set forth in our filings with the Securities and Exchange Commission, including our latest Form 10-Q and 10-K. The forward-looking statement ...

Core Insights - The healthcare sector is significantly influenced by major players like UnitedHealth Group and CVS Health, both of which integrate insurance and care delivery [1][2] - UnitedHealth's recent challenges include rising medical costs and regulatory shifts, while CVS is seen as a strong value play with a clear turnaround strategy [2] UnitedHealth Group (UNH) - UNH reported first-quarter revenues of $109.6 billion and adjusted net income of $6.6 billion, maintaining a 6% net margin [3] - The company missed earnings estimates once in the past four quarters, with an average surprise of 1.2% [4] - Medical costs surged 11.7% in the first quarter, following a 9.2% rise in 2024, with expectations of over 16% growth in 2025 [5] - UNH's pharmacy benefit manager, Optum Rx, may face regulatory challenges affecting pricing power [6] - The new CEO, Steve Hemsley, has pledged to rebuild shareholder trust after the company's first earnings miss in nearly two decades [7] CVS Health Corporation (CVS) - CVS reported first-quarter revenues of $94.6 billion and net income of $1.8 billion, with adjusted EPS of $2.25, beating last year's $1.31 by 31.6% [8][10] - The Health Care Benefits segment's medical benefit ratio improved to 87.3%, reflecting better cost control [8] - CVS has consistently beaten earnings estimates in the past four quarters, with an average surprise of 18.1% [9] - The company raised its 2025 EPS guidance to $6.00-$6.20, up from $5.75-$6.00, and anticipates $500 million in savings from retail store closures [10][14] - CVS's diversified model is showing momentum with rising retail script volumes and improved operating income across segments [12] Comparative Analysis - Zacks Consensus Estimates favor CVS, with upward revisions in EPS estimates, while UNH has seen multiple downward revisions [15] - CVS trades at a forward P/E of 10.31, compared to UNH's 12.98, indicating a more attractive risk-reward profile for CVS [16] - Year-to-date, UNH shares have dropped 39% due to medical cost concerns, while CVS shares have increased by 49.4% [18] Conclusion - UnitedHealth faces challenges with cost control and guidance uncertainties, while CVS is executing a successful turnaround with improving margins and positive analyst sentiment [21][22] - For investors seeking upside potential, CVS Health is positioned as the stronger investment option in the current healthcare landscape [22]

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits and the subsequent financial impact on the company [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, titled Miller v. Elevance Health, Inc., et al., No. 25-cv-0092, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until July 11, 2025, to request to be appointed to lead the case [2]. Group 2: Medicaid Management Issues - Elevance Health provides health insurance plans, including Medicaid benefits, which were subject to a review pause during COVID-19 that ended in 2023 [3]. - The company claimed to be monitoring cost trends related to the redetermination process and believed that the negotiated rates were adequate for the risk profiles of Medicaid patients [4]. Group 3: Financial Impact and Stock Performance - The redetermination process led to a significant increase in the acuity and utilization of Elevance's Medicaid members, which was not reflected in the company's financial guidance for 2024 [5]. - Following a statement on July 17, 2024, regarding increased Medicaid utilization, Elevance's stock price fell by $32.21, nearly 6%, from $553.14 to $520.93 [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing consensus EPS expectations by $1.33 (13.7%) due to elevated medical costs in its Medicaid business, resulting in a stock price decline of $52.61, nearly 11%, from $496.96 to $444.35 [7].

Core Insights - Hims & Hers Health has seen a significant increase in share price, up 138% in 2025, contrasting with other major healthcare stocks that have not performed as well [3][2] - Oscar Health is positioned as a potential multibagger in the healthcare sector, drawing comparisons to Hims & Hers due to its technology-first approach in transforming access to health insurance [4][9] Company Overview - Hims & Hers focuses on telemedicine services, appealing to younger demographics by providing convenient access to healthcare [6][7] - Oscar Health targets Affordable Care Act (ACA) members and small employers, aiming to leverage a tech-first digital platform to enhance customer acquisition [10][9] Financial Performance - Oscar Health has shown strong revenue growth over the past five years, with rising cash flow and liquidity, indicating a solid financial profile despite competition [12] - The total addressable market (TAM) for Oscar could expand from $160 billion to $720 billion by targeting individual coverage health reimbursement arrangements (ICHRAs) with small and medium-sized businesses [16] Market Position and Strategy - Oscar Health's market capitalization is approximately $4 billion, which is aligned with its cash balance, suggesting that the market may undervalue its insurance business [17] - The company is diversifying its revenue streams to mitigate risks associated with potential regulatory changes affecting the ACA [14][19] Investment Outlook - There are potential near-term challenges for Oscar Health, but the long-term vision is seen as compelling, with expectations for significant share price appreciation similar to Hims & Hers [19][18]

Core Viewpoint - UnitedHealth Group is exiting Latin America after incurring over $8 billion in losses since acquiring Banmedica for $2.8 billion in 2018, indicating ongoing challenges for the company and its long-term growth potential [4][5][8]. Group 1: Financial Performance - UnitedHealth's shares have decreased by 38% year to date as of June 13, reflecting significant financial struggles [1]. - The company has revised its adjusted per-share earnings guidance for the year down to between $26 and $26.50, a notable drop from the previous forecast of $29.50 to $30 [8]. - Currently, UnitedHealth's profit margin is around 5% of revenue, with rising costs impacting its financial position [6]. Group 2: Strategic Decisions - Exiting Latin America is seen as a strategic move to cut costs and improve financial health, as the region was not core to UnitedHealth's operations [6][8]. - The company is reportedly looking to offload Banmedica for approximately $1 billion to mitigate losses [5]. Group 3: Leadership Changes - The recent resignation of CEO Andrew Witty has led to Stephen Hemsley returning to lead the company, having previously served as CEO from 2006 to 2017 [9]. Group 4: Future Outlook - Despite current challenges, UnitedHealth is targeting a long-run growth rate of 13% to 16%, indicating management's belief in a potential recovery path [10]. - Shares are trading at around 13 times trailing earnings, offering a discount compared to the average S&P 500 stock, which trades at nearly 24 times earnings, suggesting a potential long-term investment opportunity [11].

Core Insights - UnitedHealth Group is increasingly relying on its Optum business to drive growth and mitigate challenges in its health benefits segment, UnitedHealthcare [1][9] - Optum has become the primary growth engine for the company, delivering stronger margins and faster revenue growth compared to the insurance unit, which is pressured by rising medical costs, particularly in Medicare Advantage [1][3] Business Segments - Optum operates across three key areas: Optum Health (care delivery and physician groups), Optum Insight (data analytics and tech solutions), and Optum Rx (pharmacy benefit management), which are less vulnerable to cost fluctuations affecting insurance operations [2] - From 2022 to 2024, Optum's revenues grew by 17.5%, 24%, and 11.6%, respectively, consistently outpacing UnitedHealthcare's growth of 12%, 12.7%, and 6% over the same period [3] Strategic Focus - UnitedHealth continues to invest heavily in expanding Optum Health's clinics and physician groups to build a more integrated care model and reduce reliance on the insurance segment, which faces regulatory and cost pressures [3][5] - Optum Insight's advanced data capabilities provide a competitive edge in risk prediction and care management across both business arms, although a cyberattack in early 2024 exposed vulnerabilities [4] Financial Performance - Optum accounted for more than half of UnitedHealth's total operating income in 2024, highlighting its importance as a profit driver [4][9] - UnitedHealth's shares have lost 38.1% year-to-date, compared to the industry's decline of 27.6% [8] Comparison with Competitors - Humana Inc. has seen weaker profits, declining about 1% over the past five years, while UnitedHealth experienced a growth of 13% [6] - Elevance Health's profits grew 11.3% over the past five years, which is below UnitedHealth but above Humana [7] Valuation Metrics - UnitedHealth trades at a forward price-to-earnings ratio of 13.18, above the industry average of 11.95, and carries a Value Score of B [11] - The Zacks Consensus Estimate for UnitedHealth's 2025 earnings is pegged at $22.28 per share, indicating a 19.5% drop from the previous year [12]

Medicare Advantage Strategy - Humana's core business is Medicare Advantage (MA), which remains an attractive sector[22, 35, 36] - The company focuses on delivering a more stable and compelling MA margin through clinical excellence and operating leverage[22] - Humana aims for a 3%+ Individual Medicare Advantage pre-tax margin[31, 55, 56] - Sustained growth in Medicare Advantage depends on superior customer satisfaction and retention[100] CenterWell and Medicaid Growth - Humana will continue to allocate capital to CenterWell and Medicaid, viewing them as strategic growth engines[22, 33] - CenterWell Primary Care is on track to reach approximately $6 billion in revenue with over 440,000-460,000 patients in 2025, with wholly-owned centers demonstrating a 32% CAGR in average contribution margin from 2021 to 2024[141, 145] - Humana expects to improve Medicaid pre-tax margin by 200-300 bps as its Medicaid presence matures[215] Financial Performance and Operating Leverage - Humana expects adjusted operating expenses to grow at less than half the rate of revenue through 2028, inclusive of investments[189] - The company anticipates a 150-180 bps improvement in operating leverage by 2028, with over 50% driven by cost reduction[199, 200] - Humana projects a 6-8% CAGR in Individual Medicare Advantage PMPM Underwriting Margin from 2025E to 2028E[209, 210]

Core Viewpoint - A class action lawsuit has been filed against UnitedHealth Group Incorporated for allegedly making false and misleading statements regarding its corporate strategy and health coverage practices, which led to investor losses during the specified class period [1][3]. Summary by Relevant Sections Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of New York on behalf of all individuals and entities who purchased UnitedHealth securities between December 3, 2024, and April 16, 2025 [1]. - Investors have until July 7, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. Allegations Against UnitedHealth - The lawsuit claims that UnitedHealth engaged in a corporate strategy of denying health coverage to increase profits and share price [3]. - This strategy allegedly resulted in regulatory scrutiny and public backlash, culminating in the murder of an individual named Brian Thompson [3]. - Following Thompson's murder, there was significant public animosity towards UnitedHealth, with many Americans expressing support for his accused killer and demanding changes in the company's practices [3]. - Despite the backlash, UnitedHealth reportedly maintained unrealistic guidance that did not reflect its changing corporate strategies [3]. - The lawsuit asserts that the public statements made by the defendants were materially false and misleading, leading to investor damages when the true details became known [3].

Core Viewpoint - Rosen Law Firm is reminding purchasers of Elevance Health, Inc. common stock about the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the Class Period from April 18, 2024, to October 16, 2024 [1][4]. Group 1: Class Action Details - Investors who purchased Elevance common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 11, 2025 [2]. - The lawsuit alleges that Elevance made false or misleading statements regarding the Medicaid redetermination process and its impact on the company's financial guidance [4]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3]. - The firm has recovered hundreds of millions of dollars for investors and has been recognized for its performance in securities class action settlements [3]. - Investors have the option to select their counsel or remain absent from the class until it is certified [6].